Nearly 5% of patients with cancer die within 1 month of undergoing surgery
the ONA take:
According to new findings presented at the American Society of Clinical Oncology's (ASCO's) 2014 Quality Care Symposium in Boston, Massachusetts, researchers have found that of the more than 1.1 million patients with cancer who underwent surgery, nearly 5% died within 1 month of their surgery.
For the study, the researchers identified more than 1.1 million patients diagnosed with cancer between 2004 and 2001. Of those, 53,498 patients died within the month after undergoing the operation.
In addition, researchers found that married patients had a 20% lower risk of dying within 1 month after surgery compared to unmarried patients. Insured patients had a 12% lower risk of dying within 1 month after surgery compared with uninsured patients, and wealthier patients had a 5% lower risk.
Also, more educated patients had a 2% lower risk of dying compared with less educated patients. In contrast, minority patients had a 13% higher risk of dying within 1 month after surgery, men had an 11% higher risk, and older patients had a 2% higher risk. Patients with advanced cancer had an 89% greater risk of dying within 1 month after surgery. The findings suggest that disparities affect adversely affect surgical outcomes.
Of more than 1.1 million patientswho underwent surgery, nearly 5% died within 1 month.
In a study of more than 1.1 million cancer patients who had surgery, Harvard researchers found that almost 5 percent died within one month of their operation. These findings are scheduled to be presented at the American Society of Clinical Oncology's 2014 Quality Care Symposium, held from Oct. 17 to 18 in Boston. The researchers found that, of the 1.1 million patients diagnosed from 2004 to 2011, 53,498 died within the month after surgery.
Specifically, married patients had a 20 percent lower risk of dying within the month after surgery; insured patients had a 12 percent lower risk; wealthier patients had a 5 percent lower risk; and more-educated patients had a 2 percent lower risk. Conversely, minority patients had a 13 percent higher risk of dying; men had an 11 percent greater risk; older patients had a 2 percent greater risk; and patients with advanced cancer had an 89 percent higher risk.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|